<DOC>
	<DOCNO>NCT01740531</DOCNO>
	<brief_summary>To evaluate efficacy safety S 303 treat red blood cell ( RBCs ) subject require chronic transfusion support due thalassemia major .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety S303 Treated Red Blood Cells ( RBCs ) Subjects With Thalassemia Major Requiring Chronic RBC Transfusion</brief_title>
	<detailed_description>To evaluate efficacy safety S 303 treat red blood cell ( RBCs ) subject require chronic transfusion support due thalassemia major .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Age ≥10 year , either gender Diagnosed thalassemia major currently participate chronic transfusion program At least one year history chronic RBC transfusion support stable transfusion requirement ( per treat physician ) Intervals least 14 day RBC transfusion All RBC component give one day transfusion episode Negative direct antiglobulin test ( DAT ) Stable iron chelation regimen Available measurement hemoglobin level one hour post transfusion Signed date informed consent form Baseline antibody specific S 303 treat RBC ( positive test , define Section 8.4.1 ) Evidence splenic hyper function define transfusion requirement &gt; 180 cc/kg/year ( 100 % hematocrit ) Splenic enlargement : spleen palpable ≥4 cm costal margin OR ≥18 cm longitudinal diameter ultrasound ( choose Investigator 's discretion accord data available ultrasound data preferable ) Any subject transition number RBC unit transfuse anticipate within 12 month study entry due growth subject ( e.g . transition 1 RBC component per transfusion cycle 2 OR transition 2 3 anticipate base weight change alone ) Alloimmunization high frequency blood group antigens extent ready provision compatible blood may feasible study ( alloimmunization alone automatic exclusion ) Current specialize treatment wash frozen RBC Requirement gamma irradiate RBC component ( would present blind difficulty due blood component label regulation Treatment medication know adversely affect RBC viability HIV infection ( defined RNA positive ) HCV ( hepatitis C ) infection ( defined RNA positive ) treat concomitant medication know suppress bone marrow Pregnant breast feed female , female child bear potential use medically approve form contraception Acute chronic medical disorder thalassemia , opinion Investigator medical monitor , may prevent subject complete participation study Participation another clinical study , either concurrently within previous 28 day , study drug device may influence red blood cell viability</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>S303 treat RBCs</keyword>
</DOC>